BRAF inhibitors are typically used in combination with inhibitors of MEK, the downstream target of BRAF, in order to delay the development of resistance to BRAF inhibitor monotherapy as in the current standard of care for late-stage BRAFV600E melanoma, dabrafenib and trametinib. Here, BRAF is linked to melanoma.